Neumora Therapeutics (NMRA) Competitors $1.64 +0.01 (+0.61%) Closing price 04:00 PM EasternExtended Trading$1.63 -0.01 (-0.55%) As of 04:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NMRA vs. GPCR, SYRE, AKBA, PHAR, CRON, TRVI, ELVN, ZYME, UPB, and MLYSShould you be buying Neumora Therapeutics stock or one of its competitors? The main competitors of Neumora Therapeutics include Structure Therapeutics (GPCR), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), Pharming Group (PHAR), Cronos Group (CRON), Trevi Therapeutics (TRVI), Enliven Therapeutics (ELVN), Zymeworks (ZYME), Upstream Bio (UPB), and Mineralys Therapeutics (MLYS). These companies are all part of the "pharmaceutical products" industry. Neumora Therapeutics vs. Its Competitors Structure Therapeutics Spyre Therapeutics Akebia Therapeutics Pharming Group Cronos Group Trevi Therapeutics Enliven Therapeutics Zymeworks Upstream Bio Mineralys Therapeutics Structure Therapeutics (NASDAQ:GPCR) and Neumora Therapeutics (NASDAQ:NMRA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation. Is GPCR or NMRA more profitable? Structure Therapeutics' return on equity of -21.31% beat Neumora Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Structure TherapeuticsN/A -21.31% -20.34% Neumora Therapeutics N/A -98.95%-87.68% Which has better earnings and valuation, GPCR or NMRA? Structure Therapeutics is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioStructure TherapeuticsN/AN/A-$122.53M-$1.05-19.01Neumora TherapeuticsN/AN/A-$243.79M-$1.57-1.04 Do institutionals and insiders believe in GPCR or NMRA? 91.8% of Structure Therapeutics shares are held by institutional investors. Comparatively, 47.7% of Neumora Therapeutics shares are held by institutional investors. 5.6% of Structure Therapeutics shares are held by insiders. Comparatively, 26.8% of Neumora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Does the media prefer GPCR or NMRA? In the previous week, Structure Therapeutics had 11 more articles in the media than Neumora Therapeutics. MarketBeat recorded 20 mentions for Structure Therapeutics and 9 mentions for Neumora Therapeutics. Neumora Therapeutics' average media sentiment score of 1.16 beat Structure Therapeutics' score of -0.40 indicating that Neumora Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Structure Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 3 Negative mention(s) 2 Very Negative mention(s) Neutral Neumora Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, GPCR or NMRA? Structure Therapeutics has a beta of -1.89, suggesting that its share price is 289% less volatile than the S&P 500. Comparatively, Neumora Therapeutics has a beta of 2.91, suggesting that its share price is 191% more volatile than the S&P 500. Do analysts prefer GPCR or NMRA? Structure Therapeutics presently has a consensus target price of $75.71, indicating a potential upside of 279.33%. Neumora Therapeutics has a consensus target price of $7.14, indicating a potential upside of 335.54%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than Structure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Structure Therapeutics 0 Sell rating(s) 0 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 3.00Neumora Therapeutics 1 Sell rating(s) 5 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.22 SummaryStructure Therapeutics beats Neumora Therapeutics on 8 of the 13 factors compared between the two stocks. Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NMRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NMRA vs. The Competition Export to ExcelMetricNeumora TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$265.60M$3.12B$5.70B$9.79BDividend YieldN/A2.21%3.77%4.10%P/E Ratio-1.0420.7930.8625.27Price / SalesN/A232.09403.8888.61Price / CashN/A41.5625.2228.45Price / Book0.929.749.516.00Net Income-$243.79M-$54.74M$3.26B$265.34M7 Day Performance13.89%8.13%4.50%2.79%1 Month Performance-11.35%7.74%5.22%1.51%1 Year Performance-85.45%18.08%31.92%25.40% Neumora Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NMRANeumora Therapeutics3.1183 of 5 stars$1.64+0.6%$7.14+335.5%-85.5%$265.60MN/A-1.04108Positive NewsGPCRStructure Therapeutics2.3061 of 5 stars$17.51+7.4%$75.71+332.4%-45.8%$939.42MN/A0.00136News CoverageSYRESpyre Therapeutics2.8943 of 5 stars$15.25+0.6%$53.40+250.2%-34.9%$915.68M$890K-4.4973Positive NewsAKBAAkebia Therapeutics3.9694 of 5 stars$3.35-2.0%$6.75+101.5%+125.7%$906.80M$160.18M-19.70430PHARPharming Group2.1478 of 5 stars$12.10-8.5%$30.00+147.9%+50.2%$906.45M$297.20M-93.08280Short Interest ↑High Trading VolumeCRONCronos Group1.0604 of 5 stars$2.67+16.1%N/A-3.3%$882.76M$117.61M53.40450High Trading VolumeTRVITrevi Therapeutics3.2444 of 5 stars$7.32-1.3%$20.38+178.3%+171.5%$870.31MN/A-17.4320Analyst RevisionELVNEnliven Therapeutics2.8636 of 5 stars$18.11+2.4%$41.20+127.5%-14.7%$868.03MN/A0.0050News CoveragePositive NewsEarnings ReportAnalyst RevisionZYMEZymeworks2.5011 of 5 stars$12.44+3.5%$21.43+72.3%+37.0%$866.86M$122.87M-8.29460UPBUpstream Bio1.94 of 5 stars$16.59+3.7%$56.50+240.6%N/A$862.55M$2.37M0.0038High Trading VolumeMLYSMineralys Therapeutics3.2007 of 5 stars$13.19+1.5%$32.25+144.5%+48.0%$847.28MN/A0.0028News CoverageEarnings ReportAnalyst Revision Related Companies and Tools Related Companies Structure Therapeutics Competitors Spyre Therapeutics Competitors Akebia Therapeutics Competitors Pharming Group Competitors Cronos Group Competitors Trevi Therapeutics Competitors Enliven Therapeutics Competitors Zymeworks Competitors Upstream Bio Competitors Mineralys Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NMRA) was last updated on 8/18/2025 by MarketBeat.com Staff From Our PartnersWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredThe stealth altcoin the financial world is underestimatingThis DeFi project could soar next When altcoin season fully kicks in—which the data suggests is happening R...Crypto 101 Media | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredTax Drain Deadline: Protect Your Wealth Before September 15thOn September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access